{
  "docId": "019de072-e9f7-73aa-b63d-f50108da815f",
  "docSlug": "8dc30a1d33d144ab07b1459d0ae0e445",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 43 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 43,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a matrix-like layout to show standard of care vs. clinical trial intervention points.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-e9f7-73aa-b63d-f50108da815f/30",
  "deckHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f",
  "deckJsonHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f.json",
  "deckAnchorHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "NSCLC = non-small cell lung cancer; AGA = actionable genomic alterations; HR+ = hormone-receptor positive; HER2-negative = human epidermal growth factor receptor 2 negative; SBRT = stereotactic body radiotherapy; CRT = chemoradiation therapy; IO = immuno-oncology; DDR = DNA damage response; CDK4/6i = cyclin-dependent kinase 4/6 inhibitor.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "783dd600-2d10-440e-b74a-7fb84337b6d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.94,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "table",
      "text": "Clinical trial matrix for NSCLC and Breast Cancer",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "479eb579-7437-43ed-976f-510a02eca396",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "At least five new Phase III trials planned to commence in the next 18 months",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffb93425-e507-4c93-9069-43dc91109bdc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Dato-DXd: initial TROP2 opportunities",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0870aa2-aee5-4cfc-add4-0b78dce0dc0e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "NxN matrix",
      "slug": "matrix-nxn",
      "agent": null,
      "layer": "slide",
      "matchId": "cc6833f2-e1ca-48c3-b284-84fd4f031b6d",
      "evidence": "table/data: Clinical trial matrix for NSCLC and Breast Cancer",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "roadmap",
      "slug": null,
      "matchId": "36095d59-eb65-43ae-b4b6-40b22d483c61",
      "evidence": "Visual mapping of clinical trial phases over treatment lines",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}